Blood Purification Equipment - Medical Devices Pipeline Assessment, 2017

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 9
2.1 Blood Purification Equipment Overview 9
3 Products under Development 10
3.1 Blood Purification Equipment - Pipeline Products by Stage of Development 10
3.2 Blood Purification Equipment - Pipeline Products by Territory 11
3.3 Blood Purification Equipment - Pipeline Products by Regulatory Path 12
3.4 Blood Purification Equipment - Pipeline Products by Estimated Approval Date 13
3.5 Blood Purification Equipment - Ongoing Clinical Trials 14
4 Blood Purification Equipment - Pipeline Products under Development by Companies 15
4.1 Blood Purification Equipment Companies - Pipeline Products by Stage of Development 15
4.2 Blood Purification Equipment - Pipeline Products by Stage of Development 16
5 Blood Purification Equipment Companies and Product Overview 17
5.1 Accel Diagnostics LLC Company Overview 17
5.1.1 Accel Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 Aethlon Medical Inc Company Overview 18
5.2.1 Aethlon Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 18
5.3 Cerus Corp Company Overview 22
5.3.1 Cerus Corp Pipeline Products & Ongoing Clinical Trials Overview 22
5.4 Children's Hospital Boston Company Overview 29
5.4.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 29
5.5 CytoSorbents Corp Company Overview 31
5.5.1 CytoSorbents Corp Pipeline Products & Ongoing Clinical Trials Overview 31
5.6 Ex Vivo Dynamics Inc Company Overview 44
5.6.1 Ex Vivo Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.7 Hansjorg Wyss Institute for Biologically Inspired Engineering Company Overview 45
5.7.1 Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview 45
5.8 Immunicom Inc Company Overview 47
5.8.1 Immunicom Inc Pipeline Products & Ongoing Clinical Trials Overview 47
5.9 McGowan Institute for Regenerative Medicine Company Overview 49
5.9.1 McGowan Institute for Regenerative Medicine Pipeline Products & Ongoing Clinical Trials Overview 49
5.10 National University of Singapore Company Overview 50
5.10.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 50
5.11 NxStage Medical Inc Company Overview 51
5.11.1 NxStage Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 51
5.12 Spectral Medical Inc Company Overview 52
5.12.1 Spectral Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
5.13 Toray Medical Co Ltd Company Overview 55
5.13.1 Toray Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 55
5.14 Zata Pharmaceuticals Inc Company Overview 56
5.14.1 Zata Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 56
6 Blood Purification Equipment- Recent Developments 57
6.1 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board 57
6.2 Jul 13, 2017: CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma 57
6.3 Jul 09, 2017: Biocon Receives GMP approval for Biologics Drug Substance facilities from French Regulator; Drug Product facility to be re-inspected 58
6.4 Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency 58
6.5 Jun 28, 2017: Aethlon Medical Announces Fiscal 2017 Results 58
6.6 Jun 22, 2017: Haemonetics Announces Formation of Scientific Advisory Council 60
6.7 Jun 14, 2017: Aethlon Medical To Present Clinical Study Results at The BIO International Convention 60
6.8 Jun 12, 2017: Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRT 61
6.9 Jun 07, 2017: Cerus Provides Update on U.S. Platelet Additive Solution Supply 61
6.10 Jun 05, 2017: Biocon Appoints Ms. Pratima Rao as Mission Director of Biocon Foundation 62
6.11 May 30, 2017: Spectral Files Final PMA Module for Toraymyxin With FDA 62
6.12 May 30, 2017: Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer 63
6.13 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 64
6.14 May 23, 2017: Cerus Provides U.S. Business Update 67
6.15 May 15, 2017: First Patient Transfused in Cerus’ Phase III RedeS Study Evaluating Safety and Efficacy of the INTERCEPT Red Blood Cell System 68
6.16 May 12, 2017: Spectral Announces First Quarter Results 69
6.17 May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited 69
6.18 May 09, 2017: Cerus Announces Exercise of Additional BARDA Contract Options Totaling $46.6 million to Support INTERCEPT Red Blood Cell System Development 70
6.19 May 09, 2017: NxStage Reports First Quarter Financial Results 70
6.20 May 08, 2017: CytoSorbents Reports First Quarter 2017 Financial Results 71
6.21 May 08, 2017: Haemonetics Reports 4th Quarter and Fiscal Year 2017 Results and Provides Fiscal 2018 Guidance 72
6.22 May 05, 2017: CytoSorbents Announces Positive REFRESH I Trial Results 74
6.23 May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s 75
6.24 May 03, 2017: Cerus Reports First Quarter 2017 Results 75
6.25 Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr 76
6.26 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 79
6.27 Apr 24, 2017: CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification 81
6.28 Apr 24, 2017: Aethlon Medical Releases Shareholder Update 82
6.29 Mar 30, 2017: Spectral Announces Fourth Quarter and Fiscal 2016 Results 83
6.30 Mar 28, 2017: Cytosorbents Strengthens Intellectual Property Portfolio With New Patents Issued In The U.S., China, Japan, Russia, And Australia 84
6.31 Mar 27, 2017: CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference 84
6.32 Mar 22, 2017: Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins Cytosorbents Scientific Advisory Board 85
6.33 Mar 20, 2017: CytoSorb Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy 86
6.34 Mar 13, 2017: Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study 87
6.35 Mar 08, 2017: Cytosorbents Highlights Activities At The 22nd International Conference On Advances In Critical Care Nephrology 88
6.36 Mar 07, 2017: U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin Treatment of Endotoxemic Septic Shock 89
6.37 Mar 07, 2017: Cerus Reports Fourth Quarter and Year End 2016 Results 89
6.38 Mar 03, 2017: CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue 91
6.39 Mar 01, 2017: Aethlon Medical Announces the Grant of a European Patent Protecting Methods of Quantifying Exosomes 92
6.40 Feb 28, 2017: NxStage Reports Fourth Quarter and Full-Year 2016 Financial Results 92
6.41 Feb 23, 2017: Spectral to File Final PMA Module With the FDA for Its Toraymyxin Treatment of Endotoxemic Septic Shock 93
6.42 Feb 22, 2017: Aethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies 94
6.43 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 95
6.44 Feb 10, 2017: Aethlon Medical Announces Fiscal 2017 Third Quarter Results 98
6.45 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 99
6.46 Feb 07, 2017: Cytosorbents To Present At The 19th Annual Bio CEO & Investor Conference 100
6.47 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 100
6.48 Feb 03, 2017: NxStage Announces Appointment of Chief Medical Officer 101
6.49 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 101
6.50 Jan 31, 2017: Immunicom Provides update on TGF-beta 104
6.51 Jan 25, 2017: Biocon Announces Changes of Key Managerial Personnel 104
6.52 Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore 104
6.53 Jan 11, 2017: Aethlon Medical Provides Clinical Study Update and a Review of 2016 Accomplishments 107
6.54 Jan 10, 2017: CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results 108
6.55 Dec 20, 2016: CytoSorbents Announces First Sales of New CytoSorb CPB Procedure Pack for Cardiac Surgery 109
6.56 Dec 19, 2016: Cerus Provides an Update on the Timeline for the INTERCEPT Blood System for Red Blood Cells in Europe 109
6.57 Dec 19, 2016: Cerus Announces Exercise Of Additional BARDA Contract Options Totaling $10,825,555 For Activities Related To Its Planned Phase Iii Trial Of The Intercept Red Blood Cell System 110
6.58 Dec 15, 2016: Aethlon Announces Initiation of Sepsis-Related Virus Study 111
6.59 Dec 12, 2016: Cytosorbents Receives $318,551 In Non-Dilutive Funding From The New Jersey Technology Business Tax Certificate Transfer Program 112
6.60 Dec 12, 2016: Arteriocyte Announces Name Change to Compass Biomedical 113
6.61 Dec 07, 2016: CytoSorb Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany 113
6.62 Dec 05, 2016: Spectral Medical appoints new board member 114
6.63 Dec 01, 2016: CytoSorb Selected for NICE MedTech Innovation Briefing in the United Kingdom 114
6.64 Nov 23, 2016: Golden Meditech Announces FY2016/2017 Interim Results 115
6.65 Nov 22, 2016: First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb 117
6.66 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 118
6.67 Nov 17, 2016: Cytosorbents Reports Highlights From The Sepseast 2016 Critical Care Congress 121
6.68 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 122
6.69 Nov 15, 2016: Adrian Thomas Joins CytoSorbents to Drive Western European Sales 123
6.70 Nov 11, 2016: Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results 123
6.71 Nov 10, 2016: Aethlon Medical Announces Fiscal 2017 Second Quarter Results 124
6.72 Nov 07, 2016: CytoSorb Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago 126
6.73 Nov 03, 2016: CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg 127
6.74 Nov 03, 2016: Cerus Reports Third Quarter 2016 Results 127
6.75 Nov 03, 2016: NxStage Reports Third Quarter Financial Results; Raises Full-Year Revenue Guidance And Cuts Net Loss Guidance In Half 129
6.76 Oct 27, 2016: Heartland Blood Centers Appoints Dr. Alexander Carterson As Its Medical Director 130
6.77 Oct 27, 2016: Catherine M. Burzik Joins Haemonetics Board of Directors 130
6.78 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 131
6.79 Oct 20, 2016: Biocon Q2 FY17 Revenue Up 21%; EBITDA Up 45% 132
6.80 Oct 13, 2016: Aethlon Medical Achieves DARPA Milestones, Including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Validation 135
6.81 Oct 13, 2016: Cerus Announces First U.S. Blood Center Customer Submits Biologics License Application to the FDA to Allow for Interstate Export of INTERCEPT Platelet Components 136
6.82 Oct 11, 2016: CytoSorbents and Foxx Medical Begin Saving Lives in Chile with CytoSorb 137
6.83 Oct 10, 2016: Cerus Announces that Hemolife Fundación Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System 137
6.84 Oct 05, 2016: CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial 138
6.85 Oct 03, 2016: Spectral Announces Clinical Trial Results 139
6.86 Oct 03, 2016: International Marketing of CytoSorb Commences at European Association for Cardio-Thoracic Surgery Conference 139
6.87 Sep 29, 2016: New Cytosorbents Website Highlights Global Growth And Innovation 140
6.88 Sep 23, 2016: CytoSorbents Expands CytoSorb into Iran with Partner Arsak 140
6.89 Sep 19, 2016: Biocon Appoints Suresh Subramanian as Head of Branded Formulations (India) Business 141
6.90 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 142
6.91 Sep 08, 2016: CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL 142
6.92 Aug 29, 2016: FDA's New Recommendation For Universal Zika Risk Reduction Of Blood Components Includes Use Of Pathogen Reduction 143
6.93 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 144
6.94 Aug 18, 2016: Spectral on Track With Regulatory Pathway for Novel Septic Shock Treatment 146
6.95 Aug 12, 2016: Spectral Announces Second Quarter Results 147
6.96 Aug 11, 2016: Aethlon Medical Announces Zika Virus Data 147
6.97 Aug 11, 2016: Aethlon Medical Announces Fiscal 2017 First Quarter Results 148
6.98 Aug 09, 2016: Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer 149
6.99 Aug 09, 2016: CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb Sales 150
6.100 Aug 08, 2016: CytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers 151
6.101 Aug 04, 2016: NxStage Reports Second Quarter Financial Results And Raises Full-Year Revenue Guidance 152
6.102 Aug 04, 2016: Cerus Reports Second Quarter 2016 Results 153
6.103 Aug 01, 2016: Haemonetics Appoints Bill Burke CFO 155
6.104 Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016 155
7 Appendix 157
7.1 Methodology 157
7.2 About GlobalData 160
7.3 Contact Us 160
7.4 Disclaimer 160
1.1 List of Tables
Table 1: Blood Purification Equipment - Pipeline Products by Stage of Development 10
Table 2: Blood Purification Equipment - Pipeline Products by Territory 11
Table 3: Blood Purification Equipment - Pipeline Products by Regulatory Path 12
Table 4: Blood Purification Equipment - Pipeline Products by Estimated Approval Date 13
Table 5: Blood Purification Equipment - Ongoing Clinical Trials 14
Table 6: Blood Purification Equipment Companies - Pipeline Products by Stage of Development 15
Table 7: Blood Purification Equipment - Pipeline Products by Stage of Development 16
Table 8: Accel Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 17
Table 9: mPharesis - Product Status 17
Table 10: mPharesis - Product Description 17
Table 11: Aethlon Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 18
Table 12: ASEPSYS Device - Product Status 18
Table 13: ASEPSYS Device - Product Description 18
Table 14: Hemopurifier - Product Status 19
Table 15: Hemopurifier - Product Description 19
Table 16: Aethlon Medical Inc - Ongoing Clinical Trials Overview 20
Table 17: Hemopurifier - Plasma Exosome Concentration in Cancer Patients Undergoing Treatment 21
Table 18: Hemopurifier - Sepsis-related Virus Study of Aethlon Hemopurifier 21
Table 19: Cerus Corp Pipeline Products & Ongoing Clinical Trials Overview 22
Table 20: INTERCEPT Blood System - Chikungunya Virus - Product Status 22
Table 21: INTERCEPT Blood System - Chikungunya Virus - Product Description 23
Table 22: INTERCEPT Blood System - Dengue Virus - Product Status 23
Table 23: INTERCEPT Blood System - Dengue Virus - Product Description 23
Table 24: INTERCEPT Blood System - Platelets - Product Status 24
Table 25: INTERCEPT Blood System - Platelets - Product Description 24
Table 26: INTERCEPT Blood System - Red Blood Cells - Product Status 24
Table 27: INTERCEPT Blood System - Red Blood Cells - Product Description 25
Table 28: INTERCEPT Blood System - Zika Virus - Product Status 25
Table 29: INTERCEPT Blood System - Zika Virus - Product Description 25
Table 30: Cerus Corp - Ongoing Clinical Trials Overview 26
Table 31: INTERCEPT Blood System - Red Blood Cells - A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion 27
Table 32: INTERCEPT Blood System - Zika Virus - A Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections (RedeS Study) and Treatment Use Open-label Extension Study 28
Table 33: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 29
Table 34: Micromagnetic-Microfluidic Device - Product Status 29
Table 35: Micromagnetic-Microfluidic Device - Product Description 29
Table 36: Surface-Modified Circuit - Product Status 30
Table 37: Surface-Modified Circuit - Product Description 30
Table 38: CytoSorbents Corp Pipeline Products & Ongoing Clinical Trials Overview 31
Table 39: BetaSorb - Product Status 31
Table 40: BetaSorb - Product Description 32
Table 41: ContrastSorb - Product Status 32
Table 42: ContrastSorb - Product Description 32
Table 43: CST 301 - Product Status 33
Table 44: CST 301 - Product Description 33
Table 45: CytoSorb - Product Status 33
Table 46: CytoSorb - Product Description 34
Table 47: CytoSorb - Cytokine Release Syndrome - Product Status 34
Table 48: CytoSorb - Cytokine Release Syndrome - Product Description 34
Table 49: CytoSorb-XL - Product Status 35
Table 50: CytoSorb-XL - Product Description 35
Table 51: DrugSorb - Product Status 35
Table 52: DrugSorb - Product Description 36
Table 53: HemoDefend - Product Status 36
Table 54: HemoDefend - Product Description 36
Table 55: CytoSorbents Corp - Ongoing Clinical Trials Overview 37
Table 56: CytoSorb - Case-observation and Compassionate Use: Use of Extracorporeal Treatment with the Cytosorb-Adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery with the Use of a Heart-lung-machine 38
Table 57: CytoSorb - Cytokine Adsorption in Sepsis and Acute Kidney Injury 38
Table 58: CytoSorb - Cytokine Clearance with Cytoabsorbant Device During Cardiac Bypass: A Pilot Study 38
Table 59: CytoSorb - Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients with Sepsis and Acute Kidney Injury 39
Table 60: CytoSorb - Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - A Randomized Study : EXCESS 39
Table 61: CytoSorb - Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients with Rhabdomyolysis 39
Table 62: CytoSorb - Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery 40
Table 63: CytoSorb - International Registry on the Use of the CytoSorb-Adsorber in ICU Patients 40
Table 64: CytoSorb - Myeloid-derived Supressor Cells in Uncomplicated Versus Complicated Patients after Cardiac Surgery 40
Table 65: CytoSorb - Pancreatitis CytoSorbents (CytoSorb) Inflammatory Cytokine Removal: A Prospective Study 41
Table 66: CytoSorb - Reduction of Inflammation Reaction to Extracorporeal Circulation in Cardiac Surgery by Interleukin Dialysis 41
Table 67: CytoSorb - Removal of Cytokine on Cardiopulmonary Bypass with CytoSorb Compared to on- and Off-pump Myocardial Revascularization 41
Table 68: CytoSorb - Removal of Cytokines During Cardiac Surgery 42
Table 69: CytoSorb - Removal of Cytokines in Patients Undergoing Cardiac Surgery with CPB (The REMOTE Study) 42
Table 70: CytoSorb - The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock 42
Table 71: CytoSorb - The Impact of Pre-emptive Intraoperative Use of Extracorporeal Cytokine Adsorption during Orthotopic Heart Transplantation 43
Table 72: Ex Vivo Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 44
Table 73: Blood Filter Device - Product Status 44
Table 74: Blood Filter Device - Product Description 44
Table 75: Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview 45
Table 76: Sepsis Therapeutic Device - Improved Version - Product Status 45
Table 77: Sepsis Therapeutic Device - Improved Version - Product Description 45
Table 78: Spleen-On-A-Chip - Product Status 46
Table 79: Spleen-On-A-Chip - Product Description 46
Table 80: Immunicom Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 81: Immunopheresis Blood-Filtering Device - Product Status 47
Table 82: Immunopheresis Blood-Filtering Device - Product Description 48
Table 83: McGowan Institute for Regenerative Medicine Pipeline Products & Ongoing Clinical Trials Overview 49
Table 84: Hemoadsorption Device - Sepsis - Product Status 49
Table 85: Hemoadsorption Device - Sepsis - Product Description 49
Table 86: National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 50
Table 87: Microfluidic Device - Sepsis - Product Status 50
Table 88: Microfluidic Device - Sepsis - Product Description 50
Table 89: NxStage Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 51
Table 90: DLT Device - Sepsis - Product Status 51
Table 91: DLT Device - Sepsis - Product Description 51
Table 92: Spectral Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
Table 93: Toraymyxin PMX-20R - Product Status 52
Table 94: Toraymyxin PMX-20R - Product Description 52
Table 95: Spectral Medical Inc - Ongoing Clinical Trials Overview 53
Table 96: Toraymyxin PMX-20R - Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection: A Single-arm Clinical Trial 54
Table 97: Toraymyxin PMX-20R - Evaluating the Use of Polymyxin B Hemoperfusion in a Prospective Non-controlled Trial in Adults 54
Table 98: Toraymyxin PMX-20R - The Effect of Endotoxin Adsorber Hemoperfusion on the Microcirculation in Patients with Severe Sepsis and Septic Shock 54
Table 99: Toray Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 55
Table 100: Toray Leukocyte Removal Column - Product Status 55
Table 101: Toray Leukocyte Removal Column - Product Description 55
Table 102: Zata Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 56
Table 103: Anti - Pathogen Device - Product Status 56
Table 104: Anti - Pathogen Device - Product Description 56
Table 105: Glossary 159

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.